- Effectiveness and safety of Jinshuibao capsules in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019: a pilot randomized, double-blind, placebo-contro
- Comparing the effects of three decoctions for coronavirus disease 2019 on severe acute respiratory syndrome coronavirus 2-related toll-like receptors-mediated inflammations
- Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation: Kinetin (MB-905) is an orally available antiviral that inhibits the replication of SARS-CoV-2 in human hepatic and pulmonary cells, making it a desirable molecule for treating severe COVID-19 due to its antiviral and anti-inflammatory activity.
- Impacts of delta and omicron variants on inactivated SARS-CoV-2 vaccine-induced T cell responses in patients with autoimmune diseases and healthy controls: Patients with autoimmune diseases are at higher risk of SARS-CoV-2 infection and may have lower immune responses to the virus due to immunosuppressant treatments. The increasing infections of variants of concern in vaccinated populations have raised concerns about the effectiveness of current vaccines.
- [Long COVID in Children: A Pediatric Center Experience]: COVID-19 has been observed to cause long-term symptoms in many people, such as the multisystemic inflammatory syndrome (MISC) and long COVID. Symptoms such as cough, fatigue, and joint pain have been observed in both adults and children.
- Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia – a pivotal double-blind, cross-over controlled study: Pulmonary microvascular occlusions can worsen SARS-CoV-2 pneumonia, leading to decreased capillary blood volume and persistent dyspnoea in patients who have “radiologically recovered” from COVID-19 pneumonia. Despite the identification of these abnormalities, there are still no therapeutic options available for clinical practice.
- Large interfacial relocation in RBD-ACE2 complex may explain fast-spreading property of Omicron: Simulations of the interactions between the Omicron variant of SARS-CoV-2 and human ACE2 show that the Omicron variant has increased binding affinity to human ACE2, which may explain its fast-spreading properties.
- The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach: The newly discovered COVID variant B.1.1.529 in Botswana has more than 30 mutations in spike and other non-spike proteins, raising concerns due to its high number of mutations. Our findings provide insights into the structural changes caused by these mutations and how they affect interaction with the host’s neutralizing antibodies.
Summary: Governor John Carney has tested positive for COVID-19 and is working from home. The 7-day average of new cases in Delaware is 135, with 158 hospitalizations. A new study has found that 71% of people with long COVID required medical treatment or were unable to work for six months or more. The FDA has withdrawn emergency use authorization for the COVID-19 antibody drug Evusheld due to its ineffectiveness against the Omicron variants now dominating the US.